Leerink Partnrs Brokers Reduce Earnings Estimates for A

Agilent Technologies, Inc. (NYSE:A) – Equities research analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for Agilent Technologies in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $1.27 per share for the quarter, down from their previous estimate of $1.32. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.51 EPS, FY2026 earnings at $6.05 EPS and FY2027 earnings at $6.60 EPS.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.58%.

Several other research analysts have also recently weighed in on the stock. Robert W. Baird lowered their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a report on Thursday. Sanford C. Bernstein lowered their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. Citigroup increased their price target on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $146.15.

Agilent Technologies Stock Up 0.6 %

Shares of A stock opened at $127.83 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The firm’s 50-day moving average is $140.64 and its 200-day moving average is $139.14. The stock has a market cap of $36.47 billion, a price-to-earnings ratio of 29.39, a PEG ratio of 3.64 and a beta of 1.07. Agilent Technologies has a 52-week low of $124.16 and a 52-week high of $155.35.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.78%. Agilent Technologies’s dividend payout ratio is 22.76%.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Institutional Trading of Agilent Technologies

A number of hedge funds have recently added to or reduced their stakes in A. AMF Tjanstepension AB acquired a new stake in Agilent Technologies in the third quarter valued at approximately $2,726,000. International Assets Investment Management LLC acquired a new stake in Agilent Technologies in the third quarter valued at approximately $12,961,000. Fortitude Family Office LLC boosted its position in Agilent Technologies by 68.3% in the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after buying an additional 95 shares in the last quarter. Integrated Advisors Network LLC boosted its position in Agilent Technologies by 2.5% in the third quarter. Integrated Advisors Network LLC now owns 3,582 shares of the medical research company’s stock valued at $532,000 after buying an additional 86 shares in the last quarter. Finally, Fidelis Capital Partners LLC boosted its position in Agilent Technologies by 57.4% in the third quarter. Fidelis Capital Partners LLC now owns 2,845 shares of the medical research company’s stock valued at $422,000 after buying an additional 1,037 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.